Connect your AI

Alamar Biosciences ALMR Convertible Debt

Other financials

Income statement

Revenue$26.0M+98.9%

Gross profit$14.5M+126%

Operating income-$12.3M-44.4%

Net income-$21.3M-178%

EPS (diluted)-$1.74-156%

Balance sheet

Cash & equivalents$64.6M—

Total debt$30.6M—

Total equity-$178.1M—

Total assets$186.5M—

Cash flow

Operating cash flow-$20.3M-55.7%

CapEx$600.0K+8.3%

Free cash flow-$20.9M-53.8%

Valuation

Market cap$1.52B—

Enterprise value$1.49B—

Returns & leverage

Debt / equity-0.2×—

Current ratio5.9×—

Where this comes from

Reported directly by Alamar Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ConvertibleDebt.

The official record: Alamar Biosciences ’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alamar Biosciences 's convertible debt.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Alamar Biosciences 's convertible debt?: Alamar Biosciences (ALMR) reported convertible debt of $65.09M in Q1 2026.